Tracleer® (bosentan) is a dual endothelin receptor antagonist and is the first approved oral medication for the treatment of pulmonary arterial hypertension (PAH). It was approved in the United States in 2001 and in the European Union in 2002. In 2007, Tracleer® (bosentan) was approved in the European Union for reducing the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease. For a complete list of countries in which Tracleer® (bosentan) has been registered and launched, click here.

Non US Residents
To access the healthcare provider section of the website, you will need to authenticate using DocCheck:

		This website contains infomation for medical professionals only. Please enter your DocCheck password.
		Username:
		Password:
	For a free DocCheck password click here.

Actelion Endothelin Research Awards (AERA) The Actelion Endothelin Research Awards (AERA) is a grant-based programme started by Actelion in 2006 and targeted to young investigators with the aim of encouraging clinical endothelin research related to heart, lung and vascular diseases. For further information please visit the AERA website. AERA website

DISCLAIMER

The information provided should not be used to diagnose, treat or advise regarding diseases. It does not replace the advice of a qualified medical professional, who should be consulted for further information. US Residents should consult www.Tracleer.com.